Taro Pharmaceutical Industries Ltd. (NYSE:TARO) Lowered to “C+” at TheStreet

TheStreet cut shares of Taro Pharmaceutical Industries Ltd. (NYSE:TARO) from a b- rating to a c+ rating in a research note issued to investors on Wednesday.

A number of other research analysts have also recently weighed in on the stock. BidaskClub cut shares of Taro Pharmaceutical Industries from a buy rating to a hold rating in a research report on Sunday, July 16th. Credit Suisse Group cut shares of Taro Pharmaceutical Industries from an outperform rating to a neutral rating in a research report on Tuesday, May 23rd.

Shares of Taro Pharmaceutical Industries (NYSE TARO) opened at 98.16 on Wednesday. The firm has a market capitalization of $3.97 billion, a price-to-earnings ratio of 10.00 and a beta of 0.64. Taro Pharmaceutical Industries has a 12-month low of $92.28 and a 12-month high of $137.38. The firm’s 50-day moving average is $113.41 and its 200-day moving average is $112.78.

Taro Pharmaceutical Industries (NYSE:TARO) last announced its quarterly earnings results on Monday, May 22nd. The company reported $2.05 earnings per share for the quarter. The firm had revenue of $196.41 million for the quarter. Taro Pharmaceutical Industries had a net margin of 49.69% and a return on equity of 20.08%. Equities research analysts forecast that Taro Pharmaceutical Industries will post $9.49 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Taro Pharmaceutical Industries Ltd. (NYSE:TARO) Lowered to “C+” at TheStreet” was reported by Transcript Daily and is the property of of Transcript Daily. If you are accessing this piece of content on another site, it was stolen and reposted in violation of United States & international trademark and copyright legislation. The legal version of this piece of content can be read at https://transcriptdaily.com/2017/08/13/taro-pharmaceutical-industries-ltd-nysetaro-lowered-to-c-at-thestreet.html.

A number of hedge funds and other institutional investors have recently made changes to their positions in TARO. Dimensional Fund Advisors LP boosted its position in shares of Taro Pharmaceutical Industries by 35.3% in the second quarter. Dimensional Fund Advisors LP now owns 178,392 shares of the company’s stock worth $19,991,000 after buying an additional 46,570 shares during the period. Citadel Advisors LLC acquired a new position in shares of Taro Pharmaceutical Industries during the second quarter worth $629,000. Parametric Portfolio Associates LLC boosted its position in shares of Taro Pharmaceutical Industries by 2.5% in the second quarter. Parametric Portfolio Associates LLC now owns 105,657 shares of the company’s stock worth $11,840,000 after buying an additional 2,547 shares during the period. California Public Employees Retirement System boosted its position in shares of Taro Pharmaceutical Industries by 1.9% in the second quarter. California Public Employees Retirement System now owns 32,800 shares of the company’s stock worth $3,676,000 after buying an additional 600 shares during the period. Finally, FMR LLC boosted its position in shares of Taro Pharmaceutical Industries by 42.2% in the second quarter. FMR LLC now owns 466,590 shares of the company’s stock worth $52,286,000 after buying an additional 138,353 shares during the period. 16.41% of the stock is currently owned by hedge funds and other institutional investors.

Taro Pharmaceutical Industries Company Profile

Taro Pharmaceutical Industries Ltd. (Taro) is a science-based pharmaceutical company. The Company operates principally through three entities: Taro Pharmaceutical Industries Ltd. (Taro Israel), and two of its subsidiaries, Taro Pharmaceuticals Inc (Taro Canada) and Taro U.SA The Company markets over 200 pharmaceutical products in over 25 countries.

Receive News & Ratings for Taro Pharmaceutical Industries Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taro Pharmaceutical Industries Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply